Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 3
Clinical Factors to Consider When Choosing a Treatment Strategy
Panelists discuss how medical professionals assess patient characteristics such as molecular profile, disease burden, and central nervous system (CNS) involvement to tailor treatment. Monotherapy may be favored for lower burden or specific mutations, whereas combination therapy is chosen for aggressive disease or resistance risk.
Video Player is loading.
Video content above is prompted by the following:
How do you weigh different patient characteristics, such as molecular profile, disease burden, or CNS involvement, when deciding between monotherapy and combination approaches?
Related Content:
